CEO SUMMARY: Pharmacogenomics, companion diagnostics, “personalized prescription drug therapy”—by any name, use of molecular diagnostics to guide clinicians in the prescribing and dosing of drugs is about to expand exponentially. Some experts predict that CYP450 testing alone will be a $1 billion business for labs in just a few years. Here’s a look at the forces driving this […]
CYP450 Testing To Have Major Clinical Impact
Analysts predict that wider clinical adoption of CYP450 testing will benefit lab industry
- By Robert Michel
- > From the Volume XIII No. 5 - April 10, 2006 Issue
- Tags: aco, bill bonello, cap, clinical lab, companion diagnostic, companion diagnostic test, Companion diagnostics, dark report, Diagnostic tests, executive war college, gene test, gene testing, genetic test, genetic testing, genomics, impac, laboratories, laboratory industry, laboratory medicine, molecular diagnostic, pathologists, pathology management, pharmacogenetic, pharmacogenomics, quest diagnostics and labcorp, the dark report, the laboratory
